Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.2). Amendment adds Cullgen financial statements through March 31, 2026 and December 31, 2025.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Amendment adds Cullgen financial statements through March 31, 2026 and December 31, 2025
- Pro forma combined balance sheet presents Gyre and Cullgen as of March 31, 2026
- Pro forma combined operations cover three months ended March 31, 2026 and year ended December 31, 2025
- Filing provides investors a clearer view of the combined company’s post-transaction financial position and operating results
Item EX-99.1 · Exhibit EX-99.2
- Audited Cullgen financial statements received an unqualified opinion under U.S. GAAP for year ended December 31, 2025
- Cash and short-term investments totaled $40.2 million against $21.0 million operating cash burn
- Accumulated deficit reached $132.2 million, with $10.8 million net loss and no product-sales revenue
- Collaboration revenue totaled $15.4 million, all from one customer, creating significant revenue concentration
- Redeemable preferred stock had a $116.0 million liquidation preference, senior to common equity holders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.